Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

GenSight Biologics S A : Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

share with twitter share with LinkedIn share with facebook
09/15/2020 | 02:55am EDT
15 September 2020
  • Press releases
  • EMA decision expected in H2 2021
  • First Marketing Authorisation Application for a gene therapy treating a mitochondrial disease
  • U.S. FDA submission on track for H2 2021

Disclaimer

Gensight Biologics SA published this content on 15 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2020 05:54:04 UTC


share with twitter share with LinkedIn share with facebook
All news about GENSIGHT BIOLOGICS S.A.
10/23GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..
AQ
10/22GENSIGHT BIOLOGICS S A : Securities Note
PU
10/22GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document
PU
10/22GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..
AQ
10/22GENSIGHT BIOLOGICS S A : successfully raises €25 million in an oversubscribed pr..
PU
10/22GENSIGHT BIOLOGICS S A : Successfully Raises €25 Million in an Oversubscribed Pr..
BU
10/21GENSIGHT BIOLOGICS S A : launches a capital increase of approximately €25 millio..
PU
10/16GENSIGHT BIOLOGICS S A : Reports Cash Position as of September 30, 2020 and Prov..
AQ
10/15GENSIGHT BIOLOGICS S A : Appoints Elsy Boglioli to its Board of Directors
AQ
10/15GENSIGHT BIOLOGICS S A : Reports Cash Position as of September 30, 2020 and Prov..
PU
More news
Financials
Sales 2020 12,5 M 14,8 M 14,8 M
Net income 2020 -16,7 M -19,7 M -19,7 M
Net cash 2020 16,7 M 19,8 M 19,8 M
P/E ratio 2020 -7,31x
Yield 2020 -
Capitalization 172 M 203 M 204 M
EV / Sales 2020 12,4x
EV / Sales 2021 11,3x
Nbr of Employees 25
Free-Float 78,3%
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,23 €
Last Close Price 4,34 €
Spread / Highest target 223%
Spread / Average Target 136%
Spread / Lowest Target 54,6%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.74.45%203
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097